| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24049 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Pembrolizumab (Keytruda®) in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 04/12/2024 |
| Rapid review completed | 10/01/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab for this indication compared with the current standard of care. |
| Full HTA commissioned by the HSE | 29/01/2025 |
| Pre-submission consultation with Applicant | 24/02/2025 |
| Full submission received from Applicant | 13/11/2025 |
| Preliminary review sent to Applicant | 30/03/2026 |
| NCPE assessment re-commenced | 30/04/2026 |
| Factual accuracy sent to Applicant | 29/06/2026 |
| NCPE assessment completed | 24/07/2026 |
| NCPE assessment outcome | The NCPE recommends that pembrolizumab (Keytruda®) be considered for reimbursement, within its licensed indication in the pMMR subpopulation, if cost-effectiveness can be improved relative to existing treatments*. There is insufficient information available to reliably inform cost-effectiveness in the dMMR subpopulation. |
*Next steps: The NCPE Assessment Report and recommendation will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.